{"id":221835,"date":"2025-09-13T20:04:58","date_gmt":"2025-09-14T01:04:58","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/09\/galimedix-starts-phase-2-fundraise-after-oral-alzheimers-candidate-clears-safety-test"},"modified":"2025-09-13T20:04:58","modified_gmt":"2025-09-14T01:04:58","slug":"galimedix-starts-phase-2-fundraise-after-oral-alzheimers-candidate-clears-safety-test","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/09\/galimedix-starts-phase-2-fundraise-after-oral-alzheimers-candidate-clears-safety-test","title":{"rendered":"Galimedix starts phase 2 fundraise after oral Alzheimer\u2019s candidate clears safety test"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/galimedix-starts-phase-2-fundraise-after-oral-alzheimers-candidate-clears-safety-test2.jpg\"><\/a><\/p>\n<p>Maryland-based biotech Galimedix Therapeutics is ready to take a big swing on its oral Alzheimer\u2019s disease candidate after no serious adverse events were reported and the small molecule successfully crossed the blood-brain barrier in a phase 1 trial.<\/p>\n<p>The first-ever clinical trial for GAL-101 tested single and multiple ascending doses of the asset in more than 100 healthy volunteers, Galimedix reported in a <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/09\/12\/3149131\/0\/en\/Progress-in-clinical-development-for-Alzheimer-s-and-other-indications-Galimedix-Therapeutics-successfully-completes-Phase-1-study-with-oral-small-molecule-GAL-101-an-amyloid-beta-.html\">Sept. 12 release<\/a>. The company is now initiating fundraising for a phase 2 trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Maryland-based biotech Galimedix Therapeutics is ready to take a big swing on its oral Alzheimer\u2019s disease candidate after no serious adverse events were reported and the small molecule successfully crossed the blood-brain barrier in a phase 1 trial. The first-ever clinical trial for GAL-101 tested single and multiple ascending doses of the asset in more [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-221835","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=221835"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221835\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=221835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=221835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=221835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}